Literature DB >> 1705478

Galanin stimulates Ca2+ mobilization, inositol phosphate accumulation, and clonal growth in small cell lung cancer cells.

T Sethi1, E Rozengurt.   

Abstract

Addition of the neuropeptide galanin to small cell lung cancer (SCLC) cells loaded with the fluorescent Ca2+ indicator fura-2-tetraacetoxymethylester causes a rapid and transient increase in the intracellular concentration of Ca2+ ([Ca2+]i) followed by homologous desensitization. Galanin increased [Ca2+]i in a concentration-dependent fashion with half-maximum effect (EC50) at 20-22 nM in H69 and H510 SCLC cells. Galanin mobilized Ca2+ from intracellular stores since its effects on [Ca2+]i were not blocked by chelation of extracellular Ca2+. Pretreatment with pertussis toxin (200 ng/ml for 4 h) did not prevent galanin-induced Ca2+ mobilization. In contrast, direct activation of protein kinase C with phorbol esters attenuated the Ca2+ response induced by galanin. The effects of galanin could be dissociated from changes in membrane potential: galanin did not increase membrane potential in SCLC cells loaded with bis(1,3-diethyltiobarbiturate)-trimethineoxonol and induced Ca2+ mobilization in depolarized SCLC cells, i.e., in cells suspended in a solution containing 145 mM K+ instead of Na+. Galanin also caused an increase in the formation of inositol phosphates in a time- and dose-dependent manner (EC50 10 nM). A rapid increase in the inositol trisphosphate fraction was followed by a slower increase in the inositol monophosphate fraction. Galanin stimulated clonal growth of both H69 and H510 cells in semisolid (agarose-containing) medium. This growth-promoting effect was sharply dependent on galanin concentration (EC50 20 nM) and markedly inhibited by [Arg6,D-Trp7,9,MePhe8]substance P, a recently identified broad spectrum neuropeptide antagonist. The results show for the first time that galanin receptors are coupled to inositol phosphate and [Ca2+]i responses in SCLC cells and, in particular, that this neuropeptide can act as a direct growth factor for these human cancer cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1705478

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  New perspectives in lung cancer. 2. Growth factors and lung cancer.

Authors:  P J Woll
Journal:  Thorax       Date:  1991-12       Impact factor: 9.139

2.  Growth factors, antagonists and lung cancer.

Authors:  P J Woll
Journal:  J R Soc Med       Date:  1993-11       Impact factor: 5.344

Review 3.  Galanin--a neuropeptide with inhibitory actions.

Authors:  K Kask; U Langel; T Bartfai
Journal:  Cell Mol Neurobiol       Date:  1995-12       Impact factor: 5.046

Review 4.  Galanin-acetylcholine interactions in rodent memory tasks and Alzheimer's disease.

Authors:  M P McDonald; J N Crawley
Journal:  J Psychiatry Neurosci       Date:  1997-11       Impact factor: 6.186

5.  Subunit composition of G(o) proteins functionally coupling galanin receptors to voltage-gated calcium channels.

Authors:  F Kalkbrenner; V E Degtiar; M Schenker; S Brendel; A Zobel; J Heschler; B Wittig; G Schultz
Journal:  EMBO J       Date:  1995-10-02       Impact factor: 11.598

6.  [Arg6,D-Trp7,9,NmePhe8]-substance P (6-11) activates JNK and induces apoptosis in small cell lung cancer cells via an oxidant-dependent mechanism.

Authors:  A C MacKinnon; R A Armstrong; C M Waters; J Cummings; J F Smyth; C Haslett; T Sethi
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

7.  Expression of a urokinase-type plasminogen activator during tumor growth leads to angiogenesis via galanin activation in tumor-bearing mice.

Authors:  Hiroyuki Yamamoto; Rina Okada; Rika Tanaka; Keiko Unno; Kazuaki Iguchi
Journal:  FEBS Open Bio       Date:  2017-10-09       Impact factor: 2.693

Review 8.  The Galaninergic System: A Target for Cancer Treatment.

Authors:  Manuel Lisardo Sánchez; Rafael Coveñas
Journal:  Cancers (Basel)       Date:  2022-08-01       Impact factor: 6.575

9.  Galanin System in Human Glioma and Pituitary Adenoma.

Authors:  Sarah Falkenstetter; Julia Leitner; Susanne M Brunner; Tim N Rieder; Barbara Kofler; Serge Weis
Journal:  Front Endocrinol (Lausanne)       Date:  2020-03-24       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.